Brought to you by 
Public offering nets $549mm for Seattle Genetics
29 Jul 2019
Executive Summary
Seattle Genetics Inc. netted $549mm through a public offering of 8.2mm common shares (including the overallotment) at $70. The company develops and sells cancer therapies, and will use the proceeds to support ongoing commercialization activities in the US and Canada for Adcetris (brentuximab vedotin, indicated for various lymphomas); for the potential upcoming launch of enfortumab vedotin (in Phase II for bladder cancer); and for additional R&D and corporate needs.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Public offering nets $549mm for Seattle Genetics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice